The first test for dementia is typically a brief cognitive screening performed in a doctor’s office during a routine visit. When a patient or family member reports memory problems or cognitive changes, the physician usually starts with a simple, quick assessment—often the Mini-Cog or Montreal Cognitive Assessment (MoCA)—rather than jumping directly to expensive neuroimaging or complex laboratory work. These screening tools take just five to ten minutes and can detect early signs of cognitive impairment well enough for the doctor to decide whether further evaluation is needed. The Mini-Cog has become the most widely used initial screening tool in primary care settings, particularly because it requires no special equipment, no scoring software, and minimal training.
A patient is asked to recall three words and draw a clock showing a specific time. Together, these tasks assess both memory and the ability to follow instructions. If results suggest possible cognitive decline, the doctor typically orders additional tests—sometimes a longer cognitive battery, blood work to rule out reversible causes like vitamin B12 deficiency or thyroid dysfunction, and possibly brain imaging. Importantly, a single screening result doesn’t diagnose dementia. Dementia diagnosis requires evidence of decline from the person’s baseline level of functioning, and it can only be confirmed after multiple visits, assessments, and sometimes consultation with a specialist like a neurologist or neuropsychologist.
Table of Contents
- Why Cognitive Screening Comes Before Other Tests
- When and Why Blood Tests and Brain Imaging Follow
- The Montreal Cognitive Assessment (MoCA) and When It’s Used
- The Role of Patient and Informant History
- Why Formal Neuropsychological Testing Is Different
- Biomarker Testing and Emerging Approaches
- The Importance of Baseline and Retesting
Why Cognitive Screening Comes Before Other Tests
Primary care doctors rely on cognitive screening first because it’s practical and evidence-based. Any patient who reports memory loss, confusion, or a family member who notices personality changes should have cognitive testing as part of their initial workup. The screening identifies whether cognitive impairment is even present—if the patient scores normally, further investigation may not be necessary, and the doctor can focus on other possible causes of reported symptoms. The Mini-Cog’s three-word recall component taps into immediate and delayed memory, which are among the first functions to decline in early Alzheimer’s disease and other dementias. The clock-drawing test is equally valuable: the inability to draw a clock showing a set time can indicate visuospatial or executive function problems that suggest dementia rather than normal aging.
Studies show that the Mini-Cog correctly identifies mild cognitive impairment or dementia roughly 80–90% of the time when compared to full neuropsychological testing. However, cognitive screening is imperfect. False positives occur—some patients without dementia score poorly due to depression, medication side effects, hearing loss, or simply anxiety during the test. Conversely, a patient with very mild disease or high education level might score normally despite early cognitive changes. This is why results always require clinical judgment and follow-up.
When and Why Blood Tests and Brain Imaging Follow
Once initial cognitive screening suggests possible cognitive impairment, most doctors order blood tests to check for reversible causes. Vitamin B12 deficiency, hypothyroidism, kidney disease, and sleep apnea can all cause cognitive symptoms that mimic dementia. Blood work is fast, inexpensive compared to brain imaging, and can identify treatable conditions that might improve if addressed.
Brain imaging—usually an MRI or sometimes a CT scan—is typically ordered next if cognitive decline is confirmed and reversible causes are ruled out. The MRI can show evidence of Alzheimer-related changes (atrophy in the hippocampus or temporal lobe), vascular damage from small strokes, or structural problems like a brain tumor. A major limitation of brain imaging is that it shows what’s happening in the brain but cannot definitively prove what type of dementia is present; cognitive testing and clinical presentation, combined with imaging findings, together point toward a diagnosis.
The Montreal Cognitive Assessment (MoCA) and When It’s Used
The Montreal Cognitive Assessment is a longer and more detailed screening tool than the Mini-Cog—it takes about 10 minutes—and tests a broader range of cognitive domains: attention, executive function, memory, language, visuospatial skills, and orientation. Some primary care clinics use it as their standard initial screen, while others reserve it for patients who score borderline on the Mini-Cog or who have specific concerns about particular cognitive domains. For example, a 68-year-old patient reports difficulty finding words and getting lost in familiar places.
The Mini-Cog might be normal if memory is relatively preserved, but the MoCA would detect language and visuospatial deficits that the shorter test missed. The MoCA is particularly sensitive to mild cognitive impairment, the stage between normal aging and dementia that some people progress from. Its major drawback is that it requires more training to administer correctly, and normative scores vary by age and education, making interpretation more complex than the Mini-Cog.
The Role of Patient and Informant History
Alongside any cognitive test, the doctor gathers history from both the patient and a family member or caregiver—ideally someone who sees the patient regularly. This informant history is crucial because patients with early dementia may not reliably report their own decline; they may minimize symptoms or forget that they forget. The caregiver or family member can describe whether the patient is losing track of bills, forgetting appointments, repeating questions, or having trouble with familiar tasks like cooking or driving.
A comparison between what the patient reports and what the family member observes often reveals patterns. A 75-year-old man says his memory is fine, but his daughter reports that he asked the same question four times during her visit and couldn’t recall her visit the following day. This informant-verified decline, combined with a cognitive test score that shows impairment, makes dementia much more likely than a test result alone.
Why Formal Neuropsychological Testing Is Different
Formal neuropsychological testing is more extensive than office-based cognitive screening and is typically done by a neuropsychologist in a specialized setting. It can take two to four hours, involves multiple tests of memory, language, attention, and executive function, and generates detailed scores and percentile rankings. Neuropsychological testing can be more sensitive to subtle changes and can sometimes point toward a specific type of dementia.
However, because it’s time-intensive, expensive, and not always covered by insurance without prior authorization, it’s rarely used as a first test. Instead, it’s usually ordered after a primary care screening has suggested dementia, especially when the diagnosis is unclear or the patient’s presentation is unusual. A limitation of very extensive testing is that some older patients become fatigued, and poor performance on later tests may reflect tiredness rather than true cognitive impairment. Additionally, neuropsychological patterns can overlap between different types of dementia (Alzheimer’s disease, vascular dementia, Lewy body dementia, frontotemporal dementia), so even detailed testing doesn’t always give a single definitive diagnosis.
Biomarker Testing and Emerging Approaches
In recent years, blood biomarkers for Alzheimer’s disease have become available, including phosphorylated tau, phosphorylated tau-181, and plasma phospho-tau181. These tests can detect Alzheimer-related pathology in the brain even before symptoms appear.
Some research centers now offer these as part of early screening, particularly when there is a strong family history of dementia or when cognitive decline has been detected but traditional diagnosis is uncertain. These biomarker tests are not yet standard in all primary care settings—they can be expensive, insurance coverage is variable, and their clinical significance (whether detecting pathology without symptoms should prompt intervention) is still being defined. However, they represent a shift toward identifying Alzheimer’s disease pathology early, before irreversible cognitive damage has occurred.
The Importance of Baseline and Retesting
One practical step often overlooked is establishing a cognitive baseline early in life, before any symptoms arise. Some health systems now offer cognitive testing as part of routine preventive care in people over 50 or 60. Having a documented normal score provides a reference point; if a patient scores notably lower years later, even if both scores fall in the “normal” range, the decline is more meaningful than looking at absolute scores alone.
Retesting is essential because dementia is a progressive condition. A single normal cognitive test doesn’t rule out future decline. Most clinical guidelines recommend cognitive screening every one to two years for patients over 65, or more frequently if initial results are borderline or if family members report ongoing changes in the patient’s thinking or memory. The pattern of decline over months or years, not a single test result, is what ultimately defines whether someone has dementia or simply normal aging.
